|1.||Eckland, David: 2 articles (08/2013 - 06/2009)|
|2.||Okano, Teruo: 1 article (01/2015)|
|3.||Yamato, Masayuki: 1 article (01/2015)|
|4.||Yano, Kazuo: 1 article (01/2015)|
|5.||Tsuyuki, Kenichiro: 1 article (01/2015)|
|6.||Watanabe, Natsumi: 1 article (01/2015)|
|7.||Holle, Lisa M: 1 article (03/2014)|
|8.||Cavanagh, Timothy T: 1 article (03/2014)|
|9.||Ram, Zvi: 1 article (08/2013)|
|10.||Ylä-Herttuala, Seppo: 1 article (08/2013)|
04/01/2008 - "Sitimagene ceradenovec, a gene therapeutic for the treatment of glioma."
11/01/2010 - "This article focuses on sitimagene ceradenovec and provides an overview of the developments in the field of gene therapy for malignant glioma."
11/01/2010 - "Sitimagene ceradenovec: a gene-based drug for the treatment of operable high-grade glioma."
04/01/2008 - "Sitimagene ceradenovec is currently undergoing a phase III clinical trial in malignant glioma patients."
08/01/2013 - "Adenovirus-mediated gene therapy with sitimagene ceradenovec followed by intravenous ganciclovir for patients with operable high-grade glioma (ASPECT): a randomised, open-label, phase 3 trial."
|3.||Drug Toxicity (Drug Safety)
|4.||Glioblastoma (Glioblastoma Multiforme)
03/01/2014 - "Potential new gene therapy option with sitimagene ceradenovec for newly diagnosed patients with glioblastoma multiforme."
08/01/2013 - "Our findings suggest that use of sitimagene ceradenovec and ganciclovir after resection can increase time to death or re-intervention in patients with newly diagnosed supratentorial glioblastoma multiforme, although the intervention did not improve overall survival. "
08/01/2013 - "We assessed the efficacy and safety of a locally applied adenovirus-mediated gene therapy with a prodrug converting enzyme (herpes-simplex-virus thymidine kinase; sitimagene ceradenovec) followed by intravenous ganciclovir in patients with newly diagnosed resectable glioblastoma. "
|2.||Glycerylphosphorylcholine (Choline Alfoscerate)